Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 21;13(1):193.
doi: 10.1038/s41408-023-00965-w.

Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M

David Fandrei  1   2 , Tony Huynh  1 , Marie Sébert  1   3 , Lorea Aguinaga  1 , Valeria Bisio  2 , Rathana Kim  4 , Emmanuelle Clappier  4 , Marion Espéli  2 , Karl Balabanian  2 , Hélène Moins-Teisserenc  2 , Antoine Toubert  2   5 , Nicolas Dulphy  2   5 , Pierre Fenaux  1   3 , Lionel Adès  1   3 , Lin-Pierre Zhao  6   7
Affiliations

Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M

David Fandrei et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Interaction of lymphopenia with MDS clinical and molecular features, and prognostic impact.
A Prevalence of lymphopenia (defined as absolute lymphocyte count (ALC) < 1.5 G/L) in IPSS-M subgroups; (B) ALC in IPSS-M subgroups (threshold of 1.5 G/L is indicated with a black bar); (C) Mutational landscape of most commonly mutated genes in MDS patients with or without lymphopenia; **p < 0.01; (D) Impact of lymphopenia on MDS patients’ overall survival (OS) according to IPSS-M strata; (E): Impact of lymphopenia on MDS patients’ leukemia-free survival (LFS) according to IPSS-M strata.
See this image and copyright information in PMC

References

    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Bernard E, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence 2022; 1: EVIDoa2200008. - PubMed
    1. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4 + T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145:64–72. doi: 10.1111/j.1365-2141.2009.07593.x. - DOI - PubMed
    1. Sternberg A. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood. 2005;106:2982–91. doi: 10.1182/blood-2005-04-1543. - DOI - PubMed
    1. Hejazi M, Manser AR, Fröbel J, Kündgen A, Zhao X, Schönberg K, et al. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 2015;100:643–52. doi: 10.3324/haematol.2014.118679. - DOI - PMC - PubMed